Allergic reactions during coronary angiography or PCI in Poland: Occurrence, trends, and long-term perspective based on the Polish ORPKI registry
Abstract
Background: Allergic reactions during coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes can affect their outcomes.
Aims: We aimed to investigate the incidence of allergic reactions and predictors of their occurrence in the catheterization laboratory.
Material and methods: The study included 1 812 994 treatment cases available in the ORPKI Polish National Registry, of which 659 372 were for women and 1 144 689 for men. Data were collected from 161 interventional cardiology centers in Poland between 2014 and 2022 and included in the retrospective analysis. An allergic reaction was defined as any hypersensitive response of the immune system manifesting as bronchospasm, asthma exacerbation, conjunctivitis, urticaria, eczema, angioedema, or anaphylactic shock.
Results: There was a decreasing incidence of allergic reactions overall, in both sexes and all age subgroups. The incidence of allergic reactions each year oscillated between 0.02% and 0.11% (P <0.001), and the most recent one was 0.02% in 2022. The incidence of allergic reaction was associated with low-molecular-weight heparin (LMWH) (OR, 23.5 [95% CI, 18.92–29.19]), glycoprotein IIb/IIIa inhibitors (GPI IIb/IIIa) (OR, 2.31 [95% CI, 1.92–2.78]), previous PCI (OR, 1.55 [95% CI, 1.34–1.8]), radiation dose (OR, 1.25 per 1000 mGy [95% CI, 1.19–1.31]), and contrast dose (OR, 1.17 per 100 ml [95% CI, 1.08–1.28]).
Conclusions: The overall incidence of acute allergic reactions in the cath lab is low and decreased significantly between 2014 and 2022. The decrease in frequency did not depend on age or sex. Independent predictors of allergic reaction incidence were the use of GPI IIb/IIIa, LMWH, and dose of contrast agent and radiation.
Keywords: allergic reactionanaphylaxiscoronary angiographyiodinated contrast mediamyocardial infarctionpercutaneous coronary intervention
References
- Grant SW, Kendall S, Goodwin AT, et al. Trends and outcomes for cardiac surgery in the United Kingdom from 2002 to 2016. JTCVS Open. 2021; 7: 259–269.
- Kataruka A, Maynard CC, Kearney KE, et al. Temporal trends in percutaneous coronary intervention and coronary artery bypass grafting: Insights from the Washington cardiac care outcomes assessment program. J Am Heart Assoc. 2020; 9(11): e015317.
- Blumenfeld O, Na'amnih W, Shapira-Daniels A, et al. Trends in coronary revascularization and ischemic heart disease-related mortality in Israel. J Am Heart Assoc. 2017; 6(2): e004734.
- Shawon MdS, Falster MO, Hsu B, et al. Trends and outcomes for percutaneous coronary intervention and coronary artery bypass graft surgery in New South Wales from 2008 to 2019. Am J Cardiol. 2023; 187: 110–118.
- Alkhouli M, Alqahtani F, Kalra A, et al. Trends in characteristics and outcomes of patients undergoing coronary revascularization in the United States, 2003–2016. JAMA Netw Open. 2020; 3(2): e1921326.
- Cacciatore S, Spadafora L, Bernardi M, et al. Management of coronary artery disease in older adults: Recent advances and gaps in evidence. J Clin Med. 2023; 12(16): 5233.
- Nairooz R, Parzynski CS, Curtis JP, et al. Contemporary trends, predictors and outcomes of perforation during percutaneous coronary intervention (from the NCDR cath PCI registry). Am J Cardiol. 2020; 130: 37–45.
- Masoudi FA, Ponirakis A, de Lemos JA, et al. Executive summary: trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries. J Am Coll Cardiol. 2017; 69(11): 1424–1426.
- Siudak Z, Wysocka-Dubielecka K, Malinowski K, et al. Psoriasis is an independent predictor of increased risk of allergic reaction during percutaneous coronary interventions. Big data analysis from the Polish National PCI Registry (ORPKI). Cardiol J. 2020; 27(3): 278–284.
- Hofmeier KS. Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int. 2015; 24(2): 58–66.
- Montone RA, Sabato V, Sgueglia GA, et al. Inflammatory mechanisms of adverse reactions to drug-eluting stents. Curr Vasc Pharmacol. 2013; 11(4): 392–398.
- Juergens CP, Khaing AMi, McIntyre GJ, et al. Adverse reactions of low osmolar non-ionic and ionic contrast media when used together or separately during percutaneous coronary intervention. Heart Lung Circ. 2005; 14(3): 172–177.
- Brockow K, Sánchez-Borges M. Hypersensitivity to contrast media and dyes. Immunol Allergy Clin North Am. 2014; 34(3): 547–564.
- Siudak Z, Hawranek M, Kleczyński P, et al. Interventional cardiology in Poland in 2022. Annual summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society (AISN PTK) and Jagiellonian University Medical College. Postepy Kardiol Interwencyjnej. 2023; 19(2): 82–85.
- Mello BH, Oliveira GB, Ramos RF, et al. Validation of the Killip–Kimball classification and late mortality after acute myocardial infarction. Arq Bras Cardiol. 2014; 103(2): 107–117.
- Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000; 284(7): 835–842.
- Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005; 60(2): 150–158.
- Park C, Bae Y, Choi S, et al. Incidence, clinical manifestations, and outcome of adverse reactions to intravenous radio-contrast media following computed tomography (Ct) in general population. Ann Allergy Asthma Immunol. 2009; 103: A44.
- Hosoya T, Yamaguchi K, Akutsu T, et al. Delayed adverse reactions to iodinated contrast media and their risk factors. Radiat Med. 2000; 18(1): 39–45.
- Aykan AÇ, Altıntaş Aykan D, Katırcıbaşı MT, et al. Management of radio-contrast allergy in radio-contrast allergic patients undergoing coronary angiography and intervention. Kardiologiia. 2020; 60(10): 62–65.
- Huang J, Bagsic S, Simon R. Characterizing overlapping radiocontrast media, shellfish, and iodine allergies. Ann Allergy Asthma Immunol. 2022; 129(5): S17.
- Kang HR, Jeong J, Brockow K. Diagnosis and prevention of hypersensitivity reactions to iodinated contrast media. Allergy Asthma Immunol Res. 2022; 14(4): 348–360.
- Nittner-Marszalska M, Bochenek G, Bodzenta-Łukaszyk A, et al. Hypersensitivity to iodine contrast media. Guidelines of the Section of Drug Hypersensitivity of the Polish Society of Allergology. Alergologia Polska - Pol J Allergol. 2018; 5(1): 51–57.
- Dery JP, Braden GA, Lincoff AM, et al. Final results of the ReoPro readministration registry. Am J Cardiol. 2004; 93(8): 979–984.
- Masood F, Hashmi S, Chaus A, et al. Complications and management of eptifibatide-induced thrombocytopenia. Ann Pharmacother. 2021; 55(12): 1467–1473.
- Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: Results of the ReoPro Readministration registry. Circulation. 2001; 104(8): 870–875.
- Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: Allergy to abciximab. Allergy. 2003; 58(7): 688–689.
- Hofmeier KS. Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int. 2015; 24(2): 58–66.
- Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362(17): 1586–1596.
- Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. CMAJ. 2009; 181(8): 477–481.
- Schindewolf M, Gobst C, Kroll H, et al. High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol. 2013; 132(1): 131–139.
- Schindewolf M, Kahle B, Lindhoff-Last E, et al. Heparin-induced skin lesions. Phlebologie. 2018; 39(1): 5–11.
- Bircher AJ, Harr T, Hohenstein L, et al. Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. Allergy. 2006; 61(12): 1432–1440.
- Schindewolf M, Lindhoff-Last E, Ludwig R, et al. Heparin-induced skin lesions. Lancet. 2012; 380(9856): 1867–1879.
- Schindewolf M, Recke A, Zillikens D, et al. Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses. Contact Dermatitis. 2017; 77(1): 35–41.
- Bircher AJ, Harr T, Hohenstein L, et al. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006; 61(12): 1432–1440.
- Yang X, Ren H, Guo X, et al. Radiation-induced skin injury: pathogenesis, treatment, and management. Aging (Albany NY). 2020; 12(22): 23379–23393.
- Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation-induced skin reactions: A systematic review of the literature. Curr Oncol. 2010; 17(4): 94–112.
- Piątek Ł, Piątek K, Skrzypek M, et al. The impact of ECG at admission and a culprit lesion on 12-month outcomes in acute myocardial infarction — analysis based on the PL-ACS Registry. Medical Studies. 2023; 39(4): 327–333.
- Cazzola M, Hanania NA, Rogliani P, et al. Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications. Kardiol Pol. 2023; 81(3): 232–241.
- Manda YR, Baradhi KM. Cardiac Catheterization Risks and Complications. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK531461/ (June 18, 2024).
- Chiu TM, Chu SY. Hypersensitivity reactions to iodinated contrast media. Biomedicines. 2022; 10(5): 1036.
- Trooboff SW, Iribarne A. Acute adverse drug reactions following cardiac catheterization: Evidence-based guidance for providers and systems. J Thorac Dis. 2019; 11(7): 2680–2684.
